Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

(CRL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. : Regulation FD Disclosure (form 8-K)

11/09/2021 | 07:40am EST

ITEM 7.01 Regulation FD Disclosure.

The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Charles River Laboratories International, Inc. ("Charles River" or the "Company") will be presenting at the Credit Suisse 30th Annual Healthcare Conference on Tuesday, November 9th, at 10:30 a.m. ET. Management of the Company intends to present an overview of the Company's strategic focus, business developments and recent trends. Included in this overview will be statements addressing Company's perspective on 2022 preliminary trends. In particular, in advance of the conference presentation, the Company has posted a slide presentation on the Investor Relations section of the Registrant's website at http://ir.criver.com which includes the following statements as to the Company's preliminary assessment of trends for 2022 in the areas of organic revenue growth, non-GAAP operating margin, staffing levels, and capital expenditures:



 · 2022 Preliminary Trends

· Expect robust, sustained demand trends to continue, resulting in

low-double-digit organic revenue growth in 2022

· Expect to generate non-GAAP operating margin improvement next year

o Continued progress towards our longer-term target of ~22.5% in 2024

· Intend to continue to effectively manage staffing levels, including increased

costs

o To accommodate growth, have been hiring ahead of our initial plan this year

o Compensation will be a headwind in 2022, but one that will help us to support

the robust client demand and achieve our growth targets that we expect in 2022

and beyond

· To add capacity to support the anticipated growth, we now believe capex will be

~9% of total revenue in 2022

o Increase primarily driven by our legacy businesses incl. Safety Assessment

The slide presentation includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained in the slide presentation are "forward-looking" rather than historic. The slide presentation also states that these and other risks relating to Charles River are set forth in the documents filed by Charles River with the Securities and Exchange Commission. With the exception of the specific statements from the slide presentation copied above, the slide presentation is not incorporated herein by reference.

© Edgar Online, source Glimpses

All news about CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
01/20Charles River Laboratories Schedules Fourth-Quarter 2021 Earnings Release and Conferenc..
BU
01/19Charles River Laboratories Partners With Valo Health to Create Drug Discovery, Developm..
MT
01/19Charles River and Valo Health Announce Strategic Partnership to Provide Clients with Ac..
BU
01/19Charles River Laboratories International, Inc and Valo Health Announce Strategic Partne..
CI
01/11Charles River Laboratories Stock Gains Following Upbeat 2022 Outlook
MT
01/11Charles River Laboratories Says Finance Chief David Smith to Retire By End of 2022, Pro..
MT
01/11CHARLES RIVER LABORATORIES INTERNATI : Change in Directors or Principal Officers, Regulati..
AQ
01/11Charles River Laboratories International, Inc. Announces David R. Smith Will Retire as ..
CI
01/11Charles River Laboratories Announces Chief Financial Officer Retirement and Transition ..
BU
01/11Charles River Laboratories International, Inc. Provides Earnings Guidance for the Full ..
CI
More news
Analyst Recommendations on CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
More recommendations
Financials (USD)
Sales 2021 3 522 M - -
Net income 2021 358 M - -
Net Debt 2021 2 484 M - -
P/E ratio 2021 46,4x
Yield 2021 -
Capitalization 16 384 M 16 384 M -
EV / Sales 2021 5,36x
EV / Sales 2022 4,65x
Nbr of Employees 18 400
Free-Float -
Chart CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Duration : Period :
Charles River Laboratories International, Inc. Technical Analysis Chart | CRL | US1598641074 | MarketScreener
Technical analysis trends CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 324,66 $
Average target price 427,08 $
Spread / Average Target 31,5%
EPS Revisions
Managers and Directors
James C. Foster General Counsel
David Ross Smith Chief Financial Officer & Executive Vice President
Arthur C. Hubbs Chief Information Officer & Senior Vice President
Birgit Girshick Chief Operating Officer
Matthew L. Daniel Senior Corporate Counsel
Sector and Competitors
1st jan.Capi. (M$)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.-11.86%16 384
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508